Invion Ltd (IVX.AX) Quote| Reuters.com
Edition:
United States

Invion Ltd (IVX.AX)

IVX.AX on Australia Stock Exchange

0.00AUD
29 Jun 2016
Change (% chg)

-- (--)
Prev Close
$0.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,471,645
52-wk High
$0.03
52-wk Low
$0.00

IVX.AX

Chart for IVX.AX

About

Invion Limited is an Australia-based clinical-stage life sciences drug development company. The Company focuses on the development of treatments for inflammatory diseases, including asthma, chronic bronchitis and lupus. It has approximately three drug assets in development across approximately four development programs. Its... (more)
No analyst recommendations are available for IVX.AX.

Overall

Beta: 2.44
Market Cap(Mil.): $4.95
Shares Outstanding(Mil.): 1,237.07
Dividend: --
Yield (%): --

Financials

  IVX.AX Industry Sector
P/E (TTM): -- 39.54 34.69
EPS (TTM): -0.02 -- --
ROI: -91.62 -6.70 14.13
ROE: -149.62 -6.13 15.35

Earnings vs. Estimates

No consensus analysis data available.

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Sadif Analytics Prime
$25.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.